NEW YORK--(BUSINESS WIRE)--Apr 14, 2025--
Bonerge Lifescience, a trusted innovator in longevity ingredients, proudly announces a historic milestone: on April 2, 2025, its premium fisetin ingredient, BeFisetin ®, has achieved Self-affirmed Generally Recognized as Safe (SA-GRAS) status in the United States. This landmark accomplishment positions Bonerge as the first company globally to secure GRAS certification for fisetin powder, setting a new global benchmark for safety and reliability in the next-generation anti-aging market.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250413308210/en/
BeFisetin: Establishing the Gold Standard to Address Chaos in the Fisetin Market
The current fisetin market is plagued by alarming quality inconsistencies. While vague claims of "Fisetin 98% HPLC" dominate as the mainstream specification, actual fisetin content in these products ranges only between 75%-85%, with significant impurities concealed under this ambiguous standard.
For plant extracts derived from non-edible sources, the removal of harmful components is critical. Fisetin, extracted from inedible Anacardiaceae plants, contains large amounts of toxic lacquer, waxes, and wood debris. Eliminating these impurities is essential to producing safe, high-quality fisetin. Yet, the absence of clear, stringent quality standards has made it impossible to verify purity, allowing low-quality products to flood the market.
Many suppliers exploit rudimentary testing methods to falsely label products as "98% HPLC," misleading consumers and perpetuating a cycle where inferior products overshadow genuine quality. This chaos forces brands to settle for subpar fisetin, stifling innovation in premium formulations.
Establishing a gold standard for fisetin quality has been Bonerge’s mission from the start. Recognizing the challenges—extensive R&D, industry-first breakthroughs, and short-term financial sacrifices—we named our product BeFisetin as a constant reminder: "To be or not to be" hinges on our commitment to redefine excellence in fisetin. BeFisetin is not just a product—it’s a pledge to restore integrity and drive progress in the fisetin industry.
What Defines the Gold Standard for Fisetin?
BeFisetin: The 1st All-Natural Fisetin to be Granted SA-GRAS
BeFisetin ® is the first all-natural fisetin to attain SA-GRAS certification. For all dietary supplement ingredients, SA-GRAS represents a critical milestone, but its significance is unparalleled in advancing fisetin as a premium raw material. This certification sets the gold standard for the industry, requiring adherence to rigorous criteria: well-defined quality specifications, scientifically validated testing protocols, GMP-compliant manufacturing environments, and comprehensive safety assessments —all of which elevate fisetin from an underregulated botanical to a clinically trusted ingredient. By establishing these benchmarks, SA-GRAS not only ensures consumer safety but also paves the way for innovation in longevity-focused formulations.
“Beyond regulatory compliance, this accomplishment reflects our foundational commitment to scientific excellence and consumer safety—principles that drive every stage of our ingredient innovation,” stated Gloria, Product Manager of Bonerge. “SA-GRAS BeFisetin ® provides brands with a scientifically validated ingredient that meets international regulatory requirements, enabling them to develop innovative products with assurance.”
A Vision for Trusted Longevity Foundation
The GRAS certification of BeFisetin ® marks the beginning of Bonerge’s mission to redefine aging. By prioritizing rigorous science and consumer safety, Bonerge aims to foster transparency in the anti-aging market, and we are committed to providing scientifically grounded solutions that empower individuals to age healthily. As global interest in senotherapeutics grows, BeFisetin ® stands at the forefront, offering brands a trusted, scalable ingredient to meet the rising demand for effective and safe longevity products.
BeFisetin®: GRAS certified Fisetin for safe use in dietary supplements and health products.
WASHINGTON (AP) — Senate Republicans will meet Tuesday to discuss next steps after the Justice Department said it would comply with a court order pausing the implementation of a $1.776 billion settlement fund designed to compensate President Donald Trump’s political allies.
GOP senators who revolted against the settlement before leaving for a Memorial Day recess two weeks ago say they want more information from the administration about the future of the fund, which could potentially go to Trump supporters who beat police and attacked the Capitol on Jan. 6, 2021. Meanwhile, Trump is reconsidering whether to move forward with it at all, according to a person familiar with his thinking.
Caught in the middle is legislation that would fund Trump’s immigration enforcement agencies for three years. Republicans abruptly left town without passing it after Democrats said they would offer amendments to scrap or scale back the judgment fund, forcing Republicans to go on the record for or against it and endangering the money for Immigration and Customs Enforcement and Border Patrol.
Returning to Washington on Monday evening, Senate Majority Leader John Thune said he wasn’t sure if the immigration spending bill would move this week.
“To be determined,” he told reporters.
The extraordinary standoff comes after Trump announced the fund with no heads up to lawmakers as part of a settlement to resolve his lawsuit against the IRS over the leak of his tax returns. When word of the settlement broke, the Senate was navigating tricky passage of the immigration legislation with an added $1 billion in White House security costs — including for Trump’s ballroom project.
Furious, Senate Republicans jettisoned the White House security money from the bill and made clear they would not pass the legislation at all unless the White House made major changes to the settlement.
“I do think the best way to handle it is if the administration decides to shut it down themselves,” Thune told reporters Monday, referring to the fund.
He said Republicans will have a better idea of how to proceed after they meet for their weekly conference lunch on Tuesday.
The Justice Department said it would comply with a ruling Friday from U.S. District Judge Leonie Brinkema, who temporarily halted the fund for two weeks. The judge scheduled a June 12 hearing for arguments on whether to extend her order.
The department said in a statement that it strongly disagrees with the ruling but would comply.
Republican senators weren't satisfied. They said Monday evening that they need more detail from the administration on what happens after that deadline before deciding next steps.
“It’s pretty clear that the president has to say very explicitly that there’s not going to be a weaponization fund,” said Senate Judiciary Committee Chairman Chuck Grassley, R-Iowa.
Oklahoma Sen. Jim Lankford said Trump administration officials “need to say what they actually mean.”
“They need to say, we’re setting this whole thing aside,” Lankford said.
Alaska Sen. Lisa Murkowski said that if the settlement is “completely pulled, then I’m satisfied. But I haven’t heard anybody say that.”
Republican Sen. John Kennedy of Louisiana said the administration already has to abide by the court decision, “that’s in the Constitution. I have to know more about their position.”
“Right now, the reconciliation bill looks like a broken arm with the bones sticking out,” Kennedy said. “It won’t move this week, in my opinion, unless we have some resolution on the weaponization account.”
The outrage of the fund came to a head last month at a closed-door meeting between senators and acting Attorney General Todd Blanche that Republican Sen. Ted Cruz of Texas described on a recent episode of his podcast as “one of the roughest meetings I’ve seen in my entire time in the Senate.”
GOP senators had been discussing several ways that they could curb the fund, including limiting who can receive payouts, changing the makeup of the commission in charge of settlement decisions, adding some sort of judicial review for applicants or scrapping the fund altogether.
Amid the backlash, a person familiar with the matter, who insisted on anonymity to discuss the president’s thinking, said Monday that Trump was reconsidering whether to move forward with the fund. But the president has not said publicly what he intends to do.
Also complicating matters is Trump’s campaign-year push to defeat GOP lawmakers whom he sees as disloyal, including some of Thune’s most reliable Republican votes in the narrow 53-47 Senate. Sens. Bill Cassidy of Louisiana and John Cornyn of Texas both lost reelection bids in May after Trump endorsed their primary opponents, and it’s unclear how supportive they’ll be of the president’s agenda going forward.
“I think it’s hard to divorce anything that happens here from what’s happening in the political atmosphere around us,” Thune said before the Senate left town.
Associated Press writers Joey Cappelletti and Eric Tucker contributed to this report.
FILE - Supporters of President Donald Trump try to break through a police barrier at the Capitol in Washington, Jan. 6, 2021. (AP Photo/Julio Cortez, File)
FILE - Rioters storm the West Front of the U.S. Capitol Jan. 6, 2021, in Washington. (AP Photo/John Minchillo, File)
